论文部分内容阅读
目的:探讨脑膜瘤微坏死与纤溶酶原激活抑制因子-1(PAI-1)和预后的关系。方法:采用ABC免疫组化方法检测90例脑膜瘤组织中PAI-1表达,分析其与临床病理因素之间的关系。结果:脑膜瘤微坏死发生率与PAI-1表达及恶性程度呈正相关(pearson列联系数分别为0.48和0.61,P<0.01);微坏死组脑膜瘤PAI-1表达阳性率85.2%(23/27),术后3年复发率40.7%,分别显著高于无微坏死组的9.5%(6/63)(P<0.01)和6.3%(P<0.01);微坏死组脑膜瘤5年生存率66.7%明显低于无微坏死组的95.2%(P<0.01)。结论:PAI-1可能是脑膜瘤发生微坏死的重要因子,脑膜瘤微坏死对判定恶性程度和预后有重要参考价值。
Objective: To investigate the relationship between meningioma micro-necrosis and plasminogen activator inhibitor-1 (PAI-1) and prognosis. Methods: ABC immunohistochemical method was used to detect the expression of PAI-1 in 90 cases of meningiomas, and its relationship with clinicopathological factors was analyzed. Results: The incidence of meningioma was positively correlated with the expression of PAI-1 and the degree of malignancy (Pearson’s correlation coefficients were 0.48 and 0.61 respectively, P <0.01). The positive rate of PAI-1 in meningioma group was 85.2% (23 / 27). The recurrence rate at 3 years after operation was 40.7%, which was significantly higher than that of non-necrotic group (9.5%, 6.3%, P <0.01) The rate of 66.7% was significantly lower than 95.2% of those without micro-necrosis (P <0.01). Conclusion: PAI-1 may be an important factor for meningioma micro-necrosis, meningioma micro-necrosis to determine the degree of malignancy and prognosis of important reference value.